Related Experiment Video
Updated: May 25, 2026

MicroRNA Amplification and Recognition through Locked-nucleic-acid In situ Hybridization as a Novel Detection and Quantification Method
Published on: October 7, 2025
MicroRNA patents in demyelinating diseases: a new diagnostic and therapeutic perspective
1Department of Physiology, Third Military Medical University, Chongqing 400038, China.
Abstract:
MicroRNAs (miRNAs, miRs) are a class of non-coding single-stranded RNAs, which can negatively regulate gene expression at posttranscriptional levels by miRNA-mRNA interaction. It has been demonstrated that miRNAs play important roles in a variety of biological process, including cell proliferation, differentiation, apoptosis, and tumorigenesis. Recent studies have shown crucial roles of specific miRNAs in controlling oligodendrocyte (OL) differentiation and myelination. Dysregulation of miRNAs is a vital event in the pathogenesis of demyelinating diseases. Furthermore, new patents of miRNAs also provide new strategies for gene therapy and miR-drug development for demyelinating diseases, especially multiple sclerosis. In this review, we briefly introduce the roles of miRNAs in OL differentiation and in the pathogenesis of demyelinating diseases, with emphasis on the implication of miRNAs patents in disease diagnostic and therapeutic perspective and its related technologies and challenges in clinical application.
Insights
MicroRNAs regulate gene expression and are crucial for oligodendrocyte differentiation and myelination. Their dysregulation is implicated in demyelinating diseases, with patents offering new therapeutic strategies.
Area of Science:
- Molecular Biology
- Neuroscience
- Genetics
Background:
- MicroRNAs (miRNAs) are non-coding RNAs regulating gene expression post-transcriptionally.
- miRNAs are vital in biological processes like cell differentiation and tumorigenesis.
- Specific miRNAs are key regulators of oligodendrocyte differentiation and myelination.
Purpose of the Study:
- To review the role of miRNAs in oligodendrocyte differentiation and myelination.
- To explore the involvement of miRNA dysregulation in demyelinating diseases.
- To discuss the implications of miRNA patents in diagnostics and therapeutics for demyelinating diseases.
Main Methods:
- Literature review of studies on miRNAs, oligodendrocyte differentiation, and demyelinating diseases.
- Analysis of current research on miRNA patents related to gene therapy and drug development.
- Examination of technological advancements and clinical challenges in miRNA-based therapies.
Main Results:
- miRNAs significantly control oligodendrocyte differentiation and myelination processes.
- Dysregulation of specific miRNAs is a critical factor in the pathogenesis of demyelinating diseases.
- miRNA patents present novel avenues for diagnostic and therapeutic interventions, particularly for multiple sclerosis.
Conclusions:
- miRNAs are essential regulators in the nervous system, with implications for demyelinating diseases.
- Understanding miRNA roles and patent landscapes can drive innovation in disease management.
- Further research and technological development are needed for successful clinical application of miRNA-based strategies.
Related Concept Videos
MicroRNAs
Microorganisms in Medicine and Therapeutics

